PARP-2 mediates cardiomyocyte aging and damage induced by doxorubicin through SIRT1 Inhibition.
Apoptosis
; 29(5-6): 816-834, 2024 Jun.
Article
in En
| MEDLINE
| ID: mdl-38281279
ABSTRACT
Doxorubicin (DOX) is an anthracycline antibiotic used as an antitumor treatment. However, its clinical application is limited due to severe side effects such as cardiotoxicity. In recent years, numerous studies have demonstrated that cellular aging has become a therapeutic target for DOX-induced cardiomyopathy. However, the underlying mechanism and specific molecular targets of DOX-induced cardiomyocyte aging remain unclear. Poly (ADP-ribose) polymerase (PARP) is a family of protein post-translational modification enzymes in eukaryotic cells, including 18 members. PARP-1, the most well-studied member of this family, has become a potential molecular target for the prevention and treatment of various cardiovascular diseases, such as DOX cardiomyopathy and heart failure. PARP-1 and PARP-2 share 69% homology in the catalytic regions. However, they do not entirely overlap in function. The role of PARP-2 in cardiovascular diseases, especially in DOX-induced cardiomyocyte aging, is less studied. In this study, we found for the first time that down-regulation of PARP-2 can inhibit DOX-induced cellular aging in cardiomyocytes. On the contrary, overexpression of PARP-2 can aggravate DOX-induced cardiomyocyte aging and injury. Further research showed that PARP-2 inhibited the expression and activity of SIRT1, which in turn was involved in the development of DOX-induced cardiomyocyte aging and injury. Our findings provide a preliminary experimental basis for establishing PARP-2 as a new target for preventing and treating DOX cardiomyopathy and related drug development.
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Doxorubicin
/
Cellular Senescence
/
Poly(ADP-ribose) Polymerases
/
Myocytes, Cardiac
/
Sirtuin 1
Limits:
Animals
/
Humans
Language:
En
Journal:
Apoptosis
Year:
2024
Type:
Article
Affiliation country:
China